文献速递痛风与晶体性关节病

加拿大安大略省老年痛风患者启动降尿酸治疗后的血清尿酸监测

Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-06-26

基于加拿大安大略省人群的回顾性队列研究纳入44,438例≥66岁新启动降尿酸治疗的痛风患者,评估启动后6个月和12个月内血清尿酸检测比例及相关因素。6个月检测率从2010年56.4%升至2019年71.3%(P<0.0001),但仍不理想;家庭医生处方者、男性医生、农村居住、较低社会经济地位与较低检测几率相关。

要点

  • 老年痛风患者启动降尿酸治疗后6个月血清尿酸检测率从2010年56.4%升至2019年71.3%(P<0.0001),总体仍不理想。
  • 与风湿科医生相比,家庭医生(OR 0.26)、内科医生(OR 0.34)、肾内科医生(OR 0.37)和其他专科(OR 0.25)检测几率更低。
  • 农村居住(OR 0.81)、较低社会经济地位(OR 0.91)和患者合并症与较低检测几率相关;慢性肾病、高血压、糖尿病及秋水仙碱/口服糖皮质激素联用(OR 1.31)与检测增加相关。

核心结论

  • 老年痛风患者启动降尿酸治疗后血清尿酸检测率不理想,但随时间改善。
  • 降尿酸治疗处方者、患者和处方特征与血清尿酸检测相关。

研究设计与样本

  • 加拿大安大略省基于人群的回顾性队列研究,纳入2010年至2019年间新配发降尿酸治疗的≥66岁痛风患者。

主要发现

  • 共纳入44,438例患者,平均±标准差年龄76.0±7.3岁,男性占64.4%。
  • 家庭医生开具了79.1%的降尿酸治疗处方。
  • 6个月血清尿酸检测率最低为2010年的56.4%,2019年升至71.3%(P<0.0001)。
  • 与风湿科医生相比,家庭医生(OR 0.26 [95%CI 0.23-0.29])、内科医生(OR 0.34 [95%CI 0.29-0.39])、肾内科医生(OR 0.37 [95%CI 0.30-0.45])和其他专科(OR 0.25 [95%CI 0.21-0.29])检测几率更低,男性医生检测几率亦更低(OR 0.87 [95%CI 0.83-0.91])。
  • 农村居住(OR 0.81 [95%CI 0.77-0.86])、较低社会经济地位(OR 0.91 [95%CI 0.85-0.97])和患者合并症与较低检测几率相关;慢性肾病、高血压、糖尿病及秋水仙碱/口服糖皮质激素联用(OR 1.31 [95%CI 1.23-1.40])与检测增加相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the proportion of, and factors associated with, older adults with gout receiving a serum urate (SUA) test after starting urate-lowering therapy (ULT). METHODS: We performed a population-based retrospective cohort study in Ontario, Canada in patients ages ≥66 years with gout, newly dispensed ULT between 2010 and 2019. We characterized patients with SUA testing within 6 and 12 months after ULT dispensation. Multilevel logistic regression clustered by ULT prescriber evaluated the factors associated with SUA monitoring within 6 months. RESULTS: We included 44,438 patients with a mean ± SD age of 76.0 ± 7.3 years and 64.4% male. Family physicians prescribed 79.1% of all ULTs. SUA testing was lowest in 2010 (56.4% at 6 months) and rose over time to 71.3% in 2019 (P < 0.0001). Compared with rheumatologists, family physicians (odds ratio [OR] 0.26 [95% confidence interval (95% CI) 0.23-0.29]), internists (OR 0.34 [95% CI 0.29-0.39]), nephrologists (OR 0.37 [95% CI 0.30-0.45]), and other specialties (OR 0.25 [95% CI 0.21-0.29]) were less likely to test SUA, as were male physicians (OR 0.87 [95% CI 0.83-0.91]). Patient factors associated with lower odds of SUA monitoring included rural residence (OR 0.81 [95% CI 0.77-0.86]), lower socioeconomic status (OR 0.91 [95% CI 0.85-0.97]), and patient comorbidities. Chronic kidney disease, hypertension, diabetes mellitus, and coprescription of colchicine/oral corticosteroids (OR 1.31 [95% CI 1.23-1.40]) were correlated with increased SUA testing. CONCLUSION: SUA testing is suboptimal among older adults with gout initiating ULT but is improving over time. ULT prescriber, patient, and prescription characteristics were correlated with SUA testing.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Kwok TSH, Kuriya B, Hawker G, et al. Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada. Arthritis Care Res (Hoboken). 2023. PMID: 37248652. doi:10.1002/acr.25167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。